@inproceedings{inproceedings, title  = {{ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2016}},

 month = {{6}},

 author = {{Neoptolemos JP and Palmer D and Ghaneh P and Valle JW and Cunningham D and Wadsley J and Meyer T and Anthoney A and Glimelius B and Falk S and Segersvard R et al}},

 doi = {{10.1200/jco.2016.34.18_suppl.lba4006}},

 volume = {{34}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{18_suppl}},

 pages = {{LBA4006-LBA4006}},

 note = {{Accessed on 2025/05/20}}}